Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Popular anti-obesity drugs continue to show cardiovascular benefits beyond weight loss, according to several new papers published in JACC, the flagship journal of the American College of Cardiology, ...

More than half of all American adults, almost 137 million people, could be candidates for the blockbuster GLP-1 drug ...

At AHA, Phase 2 results from Eli Lilly and Silence Therapeutics are seen as signs of a "major new path" of cardiovascular ...

The combination of sacubitril and valsartan reduces the cardiotoxicity related to anthracycline chemotherapy drugs, according ...

Stress after a heart attack is understandable – and new research into what drives such stress suggests that fear of another heart attack might play a significant role. Understanding how that fear ...

Among participants in the landmark ORAL Surveillance study assigned to the JAK inhibitor tofacitinib (Xeljanz) and also using ...

A large-scale clinical trial found that intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) analog ...

A study found that undergoing a cardiac ablation procedure first—before taking any antiarrhythmic therapies—may be the better ...

Experts have started thinking more broadly about what puts a person at risk for heart disease, still the leading killer in the U.S.

A study from the University of Edinburgh has revealed that long-term use of paracetamol might increase the risk of heart ...